ArticleBrain : a journal of neurology2008
Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study.
Article in Brain : a journal of neurology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 115 citations in OpenAlex.
- Cerebellar neurocan gene expression is a common pathogenic factor of trigeminal neuralgia and depression.The journal of headache and pain · 2025Article
- Association of epilepsy with trajectory of depressive symptoms in late life: The Cardiovascular Health Study.Epilepsia · 2025Article
- Clinical characterization and management of persons with comorbid epilepsy and depression: an expert opinion paper.Frontiers in pharmacology · 2025Review
- Microglia as a Game Changer in Epilepsy Comorbid Depression.Molecular neurobiology · 2024Review
- Serotonergic Neurotransmission in Limbic Regions May Reflect Therapeutic Response of Depressive Patients: A PET Study With 11C-WAY-100635 and 18F-MPPF.The international journal of neuropsychopharmacology · 2023Article
- [Depression in patients with epilepsy. Pathophysiological and clinical concepts and therapeutic strategies].Revista de neurologia · 2023Review
- Antidepressant Drugs for Seizures and Epilepsy: Where do we Stand?Current neuropharmacology · 2023Review
- The diverse role of the raphe 5-HTergic systems in epilepsy.Acta pharmacologica Sinica · 2022Review
- Role of Short Chain Fatty Acids in Epilepsy and Potential Benefits of Probiotics and Prebiotics: Targeting "Health" of Epileptic Patients.Nutrients · 2022Review
- Radiotracers for the Central Serotoninergic System.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Sudden unexpected death in epilepsy: Respiratory mechanisms.Handbook of clinical neurology · 2022Review
- Long non-coding RNAs: Potential therapeutic targets for epilepsy.Frontiers in neuroscience · 2022Review
- Mechanisms of Psychiatric Comorbidities in Epilepsy.Current topics in behavioral neurosciences · 2022Article
- [EJNMMI research · 2020Article
- Affective, neurocognitive and psychosocial disorders associated with traumatic brain injury and post-traumatic epilepsy.Neurobiology of disease · 2019Review
- Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience.Frontiers in medicine · 2019Review
- Recent advances in epilepsy.Journal of neurology · 2017Review
- Review
- Common Mechanisms Underlying Epileptogenesis and the Comorbidities of Epilepsy.Cold Spring Harbor perspectives in medicine · 2016Review
- [Depression and epilepsy : Two clinical pictures with common causes?].Der Nervenarzt · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
Brain and brainstem changes of serotoninergic 5-hydroxytryptophan (5-HT)(1A) receptor density have been reported in patients with major depressive disorder as well as in patients with temporal lobe epilepsy (TLE), using PET and the selective antagonist radiotracers [(11)C]WAY-100635 or [(18)F]FC-WAY. We used a distinct 5-HT(1A) antagonist, [(18)F]MPPF, whose binding potential depends on both receptor density and extracellular serotonin concentration, in 24 patients with drug-resistant TLE and MRI evidence of hippocampal sclerosis but without prior antidepressant exposure. Their Beck Depression Inventory (BDI-2) score ranged from 0 to 34, with nine patients having a score >11. We used a simplified reference tissue model, statistical parametric mapping and anatomical regions of interest (ROIs) to correlate parametric images of [(18)F]MPPF BP with the total BDI score and its four subclasses. The total BDI score, as well as symptoms of psychomotor anhedonia and negative cognition, correlated positively with [(18)F]MPPF BP in the raphe nuclei and in the insula contralateral to seizure onset, whereas somatic symptoms correlated positively with [(18)F]MPPF binding potential in the hippocampal/parahippocampal region ipsilateral to seizure onset, the left mid-cingulate gyrus and the inferior dorsolateral frontal cortex, bilaterally. We confirm an association of depressive symptoms in TLE patients with changes of the central serotoninergic pathways, in particular within the raphe nuclei, insula, cingulate gyrus and epileptogenic hippocampus. These changes are likely to reflect lower extracellular serotonin concentration in more depressed patients, with an upregulation of receptors a less likely alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.